GSK

Brentford, Belgium· Est. 2000

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

GSK is a fully focused, global biopharma leader with a market cap exceeding $112B, formed in 2000 and sharpened by the 2022 demerger of its consumer health business. The company leverages deep expertise in vaccines, immunology, and genetics to build a robust pipeline across its four core therapeutic areas. Its strategy is centered on disciplined R&D investment in high-value modalities, including long-acting therapies and next-generation oncology agents, to drive sustainable growth and significant public health impact.

Respiratory, Immunology & InflammationOncologyHIVInfectious Diseases

Technology Platform

A multi-platform approach leveraging human genetics, immunology/cell therapy (bispecifics, ADCs), proprietary vaccine adjuvants, long-acting injectable formulations, and AI-driven data science for target discovery and validation.

Opportunities

Significant growth potential from the rapid adoption of long-acting HIV therapies (CAB-LA, CAB+RPV) and new vaccine blockbusters (RSV).

The late-stage pipeline in oncology and immunology offers multiple near-term catalysts that could drive the next wave of revenue growth beyond current core products.

Risk Factors

Clinical and regulatory setbacks for key pipeline assets (e.g., bepirovirsen, depemokimab) pose a material risk to the growth narrative.

The company also faces ongoing litigation overhang from historical products like Zantac and future patent expiries on major revenue drivers.

Competitive Landscape

GSK faces intense competition across all core areas: in Oncology from Merck, BMS, and AstraZeneca; in Immunology from Sanofi and Novartis; in HIV from Gilead; and in Vaccines from Pfizer and Merck. Its competitive edge lies in specific technology moats (adjuvants, long-acting injectables) and focused commercial execution.